Evidence map›Paper›PMID 34786655›Full record

ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2022

SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness.

Ilaria Cavallari, Ernesto Maddaloni, Annunziata Nusca, Dario Tuccinardi, Raffaella Buzzetti, Paolo Pozzilli, Francesco Grigioni

Abstract readReview
PubMed Publisher
In one paragraph

Review in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ilaria CavallariDepartment of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128, Rome, Italy. i.cavallari@unicampus.it.
Ernesto MaddaloniDepartment of Experimental Medicine, La Sapienza University, Rome, Italy.
Annunziata NuscaDepartment of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128, Rome, Italy.
Dario TuccinardiUnit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy.
Raffaella BuzzettiDepartment of Experimental Medicine, La Sapienza University, Rome, Italy.
Paolo PozzilliUnit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy.
Francesco GrigioniDepartment of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128, Rome, Italy.
Università Campus Bio-Medico · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) represents a major global health and economic burden with still unacceptably high morbidity and mortality rates. In recent decades, novel therapeutic opportunities with a significant impact on HF outcomes have been introduced in addition to angiotensin-converting enzyme (ACE) inhibitors, β-blockers, and mineralocorticoid receptor antagonists. These include drugs such as ivabradine, sacubitril-valsartan, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The availability of an extremely large pharmacological armamentarium to face this chronic global disease highlights the importance of assessing cost effectiveness to promote sustainable healthcare. In light of the recent approval of SGLT-2 inhibitors for the treatment of HF with reduced ejection fraction, including in individuals without type 2 diabetes mellitus, the aim of this review was to provide an updated comparative evaluation of the efficacy and cost effectiveness of different pharmacological treatments for the prevention (stage A) and treatment of asymptomatic (stage B) and symptomatic (stages C-D) left ventricular dysfunction.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsVentricular Dysfunction, LeftAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsCost-Benefit AnalysisDrug CombinationsHumansStroke VolumeTetrazolesTreatment OutcomeAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationssacubitrilSodium-Glucose Transporter 2 InhibitorsTetrazoles

Identifiers

PMID34786655
OpenAlexW3212186878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.